热门资讯> 正文
Bristol Myers获得Breyanzi标签扩张的优先审查
2025-08-05 05:39
- Bristol Myers Squibb (NYSE:BMY) said that the U.S. FDA has accepted the expanded label application for its cell therapy, Breyanzi, as a potential treatment for relapsed or refractory marginal zone lymphoma with at least two prior lines of systemic therapy.
- The FDA has granted the application target action date of December 5, 2025.
- Breyanzi is approved in the U.S. for the treatment of relapsed or refractory large B-cell lymphoma
More on Bristol-Myers Squibb Company
- Bristol-Myers Squibb: Buy The Weakness
- Bristol-Myers Squibb: Declines Have Gone Too Far
- Bristol Myers: Dividend Growth, Raised Guidance, And A Double Beat
- Earnings Scorecard: 18 out of 21 healthcare firms beat earnings forecast this week
- Bristol-Myers Squibb shares snapped six-session losing streak
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
